Adverum Biotechnologies to Host a Conference Call and Webcast to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 ...
April 27 2020 - 4:01PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced the Company will host a conference call
and webcast to present new data from the OPTIC Phase1 clinical
trial of ADVM-022 intravitreal gene therapy in wet AMD. This call
will feature expert retinal specialists to discuss the new OPTIC
data and the potential treatment opportunity for ADVM-022.
The call is scheduled for Monday, May 4, 2020
beginning at 2:15 pm PDT (5:15 pm EDT). Individuals can participate
in the conference call by dialing 1-866-420-8347 (domestic) or
1-409-217-8241 (international) and refer to “Adverum
Biotechnologies’ Presentation and KOL Discussion of New Clinical
Data from OPTIC Conference Call.” It is recommended call
participants dial in 15 minutes in advance. The webcast will be
accessible under Events and Presentations in the Investors section
of the company's website. The archived audio webcast will be
available on the Adverum website following the call and will be
available for 30 days.
About Adverum
BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a
clinical-stage gene therapy company targeting unmet medical needs
in serious ocular and rare diseases. Adverum is evaluating its
novel gene therapy candidate, ADVM-022, as a one-time, intravitreal
injection for the treatment of its lead indication, wet age-related
macular degeneration. For more information, please visit
www.adverum.com
Investor and Media Inquiries:
Investors:Myesha LacyAdverum Biotechnologies,
Inc.mlacy@adverum.com1-650-649-1257
Media:Cherilyn Cecchini, M.D.LifeSci
Communicationsccecchini@lifescicomms.com1-646-876-5196
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024